nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Estropipate—osteoporosis	0.0828	0.518	CbGbCtD
Epoprostenol—CYP2C9—Cholecalciferol—osteoporosis	0.0427	0.267	CbGbCtD
Epoprostenol—CYP2C9—Estradiol—osteoporosis	0.0344	0.215	CbGbCtD
Epoprostenol—Dinoprostone—SLC51A—osteoporosis	0.00892	0.842	CrCbGaD
Epoprostenol—Dinoprostone—CYP19A1—osteoporosis	0.00168	0.158	CrCbGaD
Epoprostenol—Arthralgia—Zoledronate—osteoporosis	0.000499	0.000925	CcSEcCtD
Epoprostenol—Myalgia—Zoledronate—osteoporosis	0.000499	0.000925	CcSEcCtD
Epoprostenol—Palpitations—Conjugated Estrogens—osteoporosis	0.000499	0.000925	CcSEcCtD
Epoprostenol—Insomnia—Risedronate—osteoporosis	0.000499	0.000924	CcSEcCtD
Epoprostenol—Anxiety—Zoledronate—osteoporosis	0.000498	0.000922	CcSEcCtD
Epoprostenol—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000496	0.00092	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000496	0.000919	CcSEcCtD
Epoprostenol—Paraesthesia—Risedronate—osteoporosis	0.000495	0.000917	CcSEcCtD
Epoprostenol—Pruritus—Estropipate—osteoporosis	0.000493	0.000914	CcSEcCtD
Epoprostenol—Asthenia—Alendronate—osteoporosis	0.000493	0.000913	CcSEcCtD
Epoprostenol—Hypersensitivity—Ibandronate—osteoporosis	0.000493	0.000913	CcSEcCtD
Epoprostenol—Cough—Conjugated Estrogens—osteoporosis	0.000493	0.000913	CcSEcCtD
Epoprostenol—Dyspnoea—Risedronate—osteoporosis	0.000491	0.000911	CcSEcCtD
Epoprostenol—Hypotension—Pamidronate—osteoporosis	0.00049	0.000907	CcSEcCtD
Epoprostenol—Dry mouth—Zoledronate—osteoporosis	0.000488	0.000905	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000488	0.000904	CcSEcCtD
Epoprostenol—Fatigue—Ethinyl Estradiol—osteoporosis	0.000487	0.000903	CcSEcCtD
Epoprostenol—Pruritus—Alendronate—osteoporosis	0.000486	0.000901	CcSEcCtD
Epoprostenol—Dyspepsia—Risedronate—osteoporosis	0.000485	0.000899	CcSEcCtD
Epoprostenol—Constipation—Ethinyl Estradiol—osteoporosis	0.000483	0.000896	CcSEcCtD
Epoprostenol—Confusional state—Zoledronate—osteoporosis	0.000483	0.000894	CcSEcCtD
Epoprostenol—Hypersensitivity—Calcitriol—osteoporosis	0.000482	0.000894	CcSEcCtD
Epoprostenol—Cardiac disorder—Estradiol—osteoporosis	0.000482	0.000893	CcSEcCtD
Epoprostenol—Flushing—Estradiol—osteoporosis	0.000482	0.000893	CcSEcCtD
Epoprostenol—Arthralgia—Conjugated Estrogens—osteoporosis	0.000481	0.000891	CcSEcCtD
Epoprostenol—Chest pain—Conjugated Estrogens—osteoporosis	0.000481	0.000891	CcSEcCtD
Epoprostenol—Myalgia—Conjugated Estrogens—osteoporosis	0.000481	0.000891	CcSEcCtD
Epoprostenol—Asthenia—Ibandronate—osteoporosis	0.00048	0.000889	CcSEcCtD
Epoprostenol—Anxiety—Conjugated Estrogens—osteoporosis	0.000479	0.000888	CcSEcCtD
Epoprostenol—Nausea—Etidronic acid—osteoporosis	0.000479	0.000887	CcSEcCtD
Epoprostenol—Oedema—Zoledronate—osteoporosis	0.000479	0.000887	CcSEcCtD
Epoprostenol—Anaphylactic shock—Zoledronate—osteoporosis	0.000479	0.000887	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000477	0.000885	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000477	0.000885	CcSEcCtD
Epoprostenol—Diarrhoea—Estropipate—osteoporosis	0.000477	0.000884	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Risedronate—osteoporosis	0.000476	0.000882	CcSEcCtD
Epoprostenol—Infection—Zoledronate—osteoporosis	0.000475	0.000881	CcSEcCtD
Epoprostenol—Fatigue—Risedronate—osteoporosis	0.000475	0.000881	CcSEcCtD
Epoprostenol—Insomnia—Pamidronate—osteoporosis	0.000474	0.000878	CcSEcCtD
Epoprostenol—Pruritus—Ibandronate—osteoporosis	0.000473	0.000877	CcSEcCtD
Epoprostenol—Pain—Risedronate—osteoporosis	0.000471	0.000873	CcSEcCtD
Epoprostenol—Constipation—Risedronate—osteoporosis	0.000471	0.000873	CcSEcCtD
Epoprostenol—Angiopathy—Estradiol—osteoporosis	0.000471	0.000873	CcSEcCtD
Epoprostenol—Shock—Zoledronate—osteoporosis	0.000471	0.000873	CcSEcCtD
Epoprostenol—Paraesthesia—Pamidronate—osteoporosis	0.00047	0.000872	CcSEcCtD
Epoprostenol—Diarrhoea—Alendronate—osteoporosis	0.00047	0.000871	CcSEcCtD
Epoprostenol—Asthenia—Calcitriol—osteoporosis	0.00047	0.00087	CcSEcCtD
Epoprostenol—Nervous system disorder—Zoledronate—osteoporosis	0.000469	0.00087	CcSEcCtD
Epoprostenol—Thrombocytopenia—Zoledronate—osteoporosis	0.000469	0.000868	CcSEcCtD
Epoprostenol—Mediastinal disorder—Estradiol—osteoporosis	0.000468	0.000867	CcSEcCtD
Epoprostenol—Dyspnoea—Pamidronate—osteoporosis	0.000467	0.000866	CcSEcCtD
Epoprostenol—Tachycardia—Zoledronate—osteoporosis	0.000467	0.000866	CcSEcCtD
Epoprostenol—Chills—Estradiol—osteoporosis	0.000466	0.000863	CcSEcCtD
Epoprostenol—Somnolence—Pamidronate—osteoporosis	0.000466	0.000863	CcSEcCtD
Epoprostenol—Skin disorder—Zoledronate—osteoporosis	0.000465	0.000861	CcSEcCtD
Epoprostenol—Pruritus—Calcitriol—osteoporosis	0.000463	0.000858	CcSEcCtD
Epoprostenol—Hyperhidrosis—Zoledronate—osteoporosis	0.000463	0.000857	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000462	0.000857	CcSEcCtD
Epoprostenol—Diarrhoea—Raloxifene—osteoporosis	0.000462	0.000857	CcSEcCtD
Epoprostenol—Dyspepsia—Pamidronate—osteoporosis	0.000461	0.000855	CcSEcCtD
Epoprostenol—Dizziness—Estropipate—osteoporosis	0.000461	0.000855	CcSEcCtD
Epoprostenol—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000461	0.000854	CcSEcCtD
Epoprostenol—Oedema—Conjugated Estrogens—osteoporosis	0.000461	0.000854	CcSEcCtD
Epoprostenol—Infection—Conjugated Estrogens—osteoporosis	0.000458	0.000848	CcSEcCtD
Epoprostenol—Diarrhoea—Ibandronate—osteoporosis	0.000458	0.000848	CcSEcCtD
Epoprostenol—Anorexia—Zoledronate—osteoporosis	0.000456	0.000845	CcSEcCtD
Epoprostenol—Decreased appetite—Pamidronate—osteoporosis	0.000455	0.000844	CcSEcCtD
Epoprostenol—Mental disorder—Estradiol—osteoporosis	0.000455	0.000843	CcSEcCtD
Epoprostenol—Dizziness—Alendronate—osteoporosis	0.000454	0.000842	CcSEcCtD
Epoprostenol—Shock—Conjugated Estrogens—osteoporosis	0.000453	0.00084	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000452	0.000838	CcSEcCtD
Epoprostenol—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000452	0.000837	CcSEcCtD
Epoprostenol—Fatigue—Pamidronate—osteoporosis	0.000452	0.000837	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Risedronate—osteoporosis	0.000451	0.000835	CcSEcCtD
Epoprostenol—Tachycardia—Conjugated Estrogens—osteoporosis	0.00045	0.000833	CcSEcCtD
Epoprostenol—Urticaria—Ethinyl Estradiol—osteoporosis	0.000449	0.000832	CcSEcCtD
Epoprostenol—Pain—Pamidronate—osteoporosis	0.000448	0.00083	CcSEcCtD
Epoprostenol—Constipation—Pamidronate—osteoporosis	0.000448	0.00083	CcSEcCtD
Epoprostenol—Diarrhoea—Calcitriol—osteoporosis	0.000448	0.00083	CcSEcCtD
Epoprostenol—Skin disorder—Conjugated Estrogens—osteoporosis	0.000448	0.000829	CcSEcCtD
Epoprostenol—Hypotension—Zoledronate—osteoporosis	0.000447	0.000829	CcSEcCtD
Epoprostenol—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000447	0.000828	CcSEcCtD
Epoprostenol—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000447	0.000828	CcSEcCtD
Epoprostenol—Dizziness—Raloxifene—osteoporosis	0.000447	0.000828	CcSEcCtD
Epoprostenol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000446	0.000826	CcSEcCtD
Epoprostenol—Flatulence—Estradiol—osteoporosis	0.000445	0.000825	CcSEcCtD
Epoprostenol—Tension—Estradiol—osteoporosis	0.000443	0.000822	CcSEcCtD
Epoprostenol—Vomiting—Estropipate—osteoporosis	0.000443	0.000822	CcSEcCtD
Epoprostenol—Dizziness—Ibandronate—osteoporosis	0.000442	0.00082	CcSEcCtD
Epoprostenol—Rash—Estropipate—osteoporosis	0.00044	0.000815	CcSEcCtD
Epoprostenol—Dermatitis—Estropipate—osteoporosis	0.000439	0.000814	CcSEcCtD
Epoprostenol—Anorexia—Conjugated Estrogens—osteoporosis	0.000439	0.000814	CcSEcCtD
Epoprostenol—Nervousness—Estradiol—osteoporosis	0.000439	0.000813	CcSEcCtD
Epoprostenol—Urticaria—Risedronate—osteoporosis	0.000438	0.000811	CcSEcCtD
Epoprostenol—Back pain—Estradiol—osteoporosis	0.000437	0.00081	CcSEcCtD
Epoprostenol—Headache—Estropipate—osteoporosis	0.000437	0.00081	CcSEcCtD
Epoprostenol—Vomiting—Alendronate—osteoporosis	0.000437	0.000809	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000436	0.000808	CcSEcCtD
Epoprostenol—Abdominal pain—Risedronate—osteoporosis	0.000436	0.000807	CcSEcCtD
Epoprostenol—Body temperature increased—Risedronate—osteoporosis	0.000436	0.000807	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—TNF—osteoporosis	0.000435	0.0015	CbGpPWpGaD
Epoprostenol—Muscle spasms—Estradiol—osteoporosis	0.000434	0.000805	CcSEcCtD
Epoprostenol—Rash—Alendronate—osteoporosis	0.000433	0.000803	CcSEcCtD
Epoprostenol—Insomnia—Zoledronate—osteoporosis	0.000433	0.000802	CcSEcCtD
Epoprostenol—Dermatitis—Alendronate—osteoporosis	0.000433	0.000802	CcSEcCtD
Epoprostenol—Hypotension—Conjugated Estrogens—osteoporosis	0.000431	0.000798	CcSEcCtD
Epoprostenol—Headache—Alendronate—osteoporosis	0.00043	0.000797	CcSEcCtD
Epoprostenol—Paraesthesia—Zoledronate—osteoporosis	0.00043	0.000796	CcSEcCtD
Epoprostenol—Vomiting—Raloxifene—osteoporosis	0.00043	0.000796	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Pamidronate—osteoporosis	0.000428	0.000794	CcSEcCtD
Epoprostenol—Dyspnoea—Zoledronate—osteoporosis	0.000427	0.000791	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CALCA—osteoporosis	0.000426	0.00147	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CALCA—osteoporosis	0.000426	0.00147	CbGpPWpGaD
Epoprostenol—Rash—Raloxifene—osteoporosis	0.000426	0.000789	CcSEcCtD
Epoprostenol—Dermatitis—Raloxifene—osteoporosis	0.000426	0.000789	CcSEcCtD
Epoprostenol—Somnolence—Zoledronate—osteoporosis	0.000425	0.000788	CcSEcCtD
Epoprostenol—Vomiting—Ibandronate—osteoporosis	0.000425	0.000788	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—FGB—osteoporosis	0.000424	0.00146	CbGpPWpGaD
Epoprostenol—Tremor—Estradiol—osteoporosis	0.000423	0.000785	CcSEcCtD
Epoprostenol—Headache—Raloxifene—osteoporosis	0.000423	0.000784	CcSEcCtD
Epoprostenol—Rash—Ibandronate—osteoporosis	0.000422	0.000781	CcSEcCtD
Epoprostenol—Dermatitis—Ibandronate—osteoporosis	0.000421	0.000781	CcSEcCtD
Epoprostenol—Dyspepsia—Zoledronate—osteoporosis	0.000421	0.000781	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00042	0.000778	CcSEcCtD
Epoprostenol—Headache—Ibandronate—osteoporosis	0.000419	0.000776	CcSEcCtD
Epoprostenol—Insomnia—Conjugated Estrogens—osteoporosis	0.000417	0.000772	CcSEcCtD
Epoprostenol—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000417	0.000772	CcSEcCtD
Epoprostenol—Vomiting—Calcitriol—osteoporosis	0.000416	0.000771	CcSEcCtD
Epoprostenol—Decreased appetite—Zoledronate—osteoporosis	0.000416	0.000771	CcSEcCtD
Epoprostenol—Agitation—Estradiol—osteoporosis	0.000415	0.00077	CcSEcCtD
Epoprostenol—Nausea—Estropipate—osteoporosis	0.000414	0.000768	CcSEcCtD
Epoprostenol—Abdominal pain—Pamidronate—osteoporosis	0.000414	0.000768	CcSEcCtD
Epoprostenol—Body temperature increased—Pamidronate—osteoporosis	0.000414	0.000768	CcSEcCtD
Epoprostenol—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000414	0.000767	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000413	0.000766	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000413	0.00142	CbGpPWpGaD
Epoprostenol—Rash—Calcitriol—osteoporosis	0.000413	0.000765	CcSEcCtD
Epoprostenol—Fatigue—Zoledronate—osteoporosis	0.000413	0.000765	CcSEcCtD
Epoprostenol—Dermatitis—Calcitriol—osteoporosis	0.000412	0.000764	CcSEcCtD
Epoprostenol—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000411	0.000761	CcSEcCtD
Epoprostenol—Headache—Calcitriol—osteoporosis	0.00041	0.00076	CcSEcCtD
Epoprostenol—Somnolence—Conjugated Estrogens—osteoporosis	0.00041	0.000759	CcSEcCtD
Epoprostenol—Pain—Zoledronate—osteoporosis	0.000409	0.000758	CcSEcCtD
Epoprostenol—Constipation—Zoledronate—osteoporosis	0.000409	0.000758	CcSEcCtD
Epoprostenol—Nausea—Alendronate—osteoporosis	0.000408	0.000756	CcSEcCtD
Epoprostenol—PTGIS—Disease—ACP5—osteoporosis	0.000407	0.0014	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Risedronate—osteoporosis	0.000406	0.000752	CcSEcCtD
Epoprostenol—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000406	0.000752	CcSEcCtD
Epoprostenol—Asthenia—Ethinyl Estradiol—osteoporosis	0.000406	0.000752	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—SOST—osteoporosis	0.000405	0.0014	CbGpPWpGaD
Epoprostenol—Syncope—Estradiol—osteoporosis	0.000405	0.000751	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IGF1—osteoporosis	0.000405	0.0014	CbGpPWpGaD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000403	0.00139	CbGpPWpGaD
Epoprostenol—Nausea—Raloxifene—osteoporosis	0.000401	0.000744	CcSEcCtD
Epoprostenol—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000401	0.000742	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—POMC—osteoporosis	0.0004	0.00138	CbGpPWpGaD
Epoprostenol—Pruritus—Ethinyl Estradiol—osteoporosis	0.0004	0.000741	CcSEcCtD
Epoprostenol—Palpitations—Estradiol—osteoporosis	0.000399	0.00074	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000398	0.00137	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000398	0.000737	CcSEcCtD
Epoprostenol—Fatigue—Conjugated Estrogens—osteoporosis	0.000397	0.000736	CcSEcCtD
Epoprostenol—Nausea—Ibandronate—osteoporosis	0.000397	0.000736	CcSEcCtD
Epoprostenol—Loss of consciousness—Estradiol—osteoporosis	0.000397	0.000736	CcSEcCtD
Epoprostenol—Asthenia—Risedronate—osteoporosis	0.000395	0.000733	CcSEcCtD
Epoprostenol—Cough—Estradiol—osteoporosis	0.000394	0.000731	CcSEcCtD
Epoprostenol—Pain—Conjugated Estrogens—osteoporosis	0.000394	0.00073	CcSEcCtD
Epoprostenol—Constipation—Conjugated Estrogens—osteoporosis	0.000394	0.00073	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Zoledronate—osteoporosis	0.000391	0.000725	CcSEcCtD
Epoprostenol—Pruritus—Risedronate—osteoporosis	0.00039	0.000723	CcSEcCtD
Epoprostenol—Nausea—Calcitriol—osteoporosis	0.000389	0.000721	CcSEcCtD
Epoprostenol—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000387	0.000717	CcSEcCtD
Epoprostenol—Hypersensitivity—Pamidronate—osteoporosis	0.000386	0.000715	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000386	0.00133	CbGpPWpGaD
Epoprostenol—Arthralgia—Estradiol—osteoporosis	0.000385	0.000713	CcSEcCtD
Epoprostenol—Myalgia—Estradiol—osteoporosis	0.000385	0.000713	CcSEcCtD
Epoprostenol—Chest pain—Estradiol—osteoporosis	0.000385	0.000713	CcSEcCtD
Epoprostenol—Anxiety—Estradiol—osteoporosis	0.000383	0.00071	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000382	0.000708	CcSEcCtD
Epoprostenol—Urticaria—Zoledronate—osteoporosis	0.00038	0.000705	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.00038	0.00131	CbGpPWpGaD
Epoprostenol—Body temperature increased—Zoledronate—osteoporosis	0.000378	0.000701	CcSEcCtD
Epoprostenol—Abdominal pain—Zoledronate—osteoporosis	0.000378	0.000701	CcSEcCtD
Epoprostenol—PTGIS—Disease—TPI1—osteoporosis	0.000378	0.0013	CbGpPWpGaD
Epoprostenol—Diarrhoea—Risedronate—osteoporosis	0.000377	0.000699	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000377	0.000698	CcSEcCtD
Epoprostenol—Dry mouth—Estradiol—osteoporosis	0.000376	0.000697	CcSEcCtD
Epoprostenol—Asthenia—Pamidronate—osteoporosis	0.000376	0.000697	CcSEcCtD
Epoprostenol—Dizziness—Ethinyl Estradiol—osteoporosis	0.000374	0.000693	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—SOST—osteoporosis	0.000373	0.00129	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SOST—osteoporosis	0.000373	0.00129	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—IDH2—osteoporosis	0.000372	0.00128	CbGpPWpGaD
Epoprostenol—Confusional state—Estradiol—osteoporosis	0.000372	0.000689	CcSEcCtD
Epoprostenol—Pruritus—Pamidronate—osteoporosis	0.000371	0.000687	CcSEcCtD
Epoprostenol—Anaphylactic shock—Estradiol—osteoporosis	0.000369	0.000683	CcSEcCtD
Epoprostenol—Oedema—Estradiol—osteoporosis	0.000369	0.000683	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CALCR—osteoporosis	0.000367	0.00126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTH1R—osteoporosis	0.000367	0.00126	CbGpPWpGaD
Epoprostenol—Infection—Estradiol—osteoporosis	0.000366	0.000679	CcSEcCtD
Epoprostenol—Urticaria—Conjugated Estrogens—osteoporosis	0.000366	0.000678	CcSEcCtD
Epoprostenol—Dizziness—Risedronate—osteoporosis	0.000364	0.000675	CcSEcCtD
Epoprostenol—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000364	0.000675	CcSEcCtD
Epoprostenol—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000364	0.000675	CcSEcCtD
Epoprostenol—Shock—Estradiol—osteoporosis	0.000363	0.000672	CcSEcCtD
Epoprostenol—Nervous system disorder—Estradiol—osteoporosis	0.000362	0.00067	CcSEcCtD
Epoprostenol—Tachycardia—Estradiol—osteoporosis	0.00036	0.000667	CcSEcCtD
Epoprostenol—Vomiting—Ethinyl Estradiol—osteoporosis	0.000359	0.000666	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—PTH—osteoporosis	0.000359	0.00124	CbGpPWpGaD
Epoprostenol—Diarrhoea—Pamidronate—osteoporosis	0.000359	0.000664	CcSEcCtD
Epoprostenol—Skin disorder—Estradiol—osteoporosis	0.000358	0.000664	CcSEcCtD
Epoprostenol—Hyperhidrosis—Estradiol—osteoporosis	0.000357	0.000661	CcSEcCtD
Epoprostenol—Rash—Ethinyl Estradiol—osteoporosis	0.000356	0.000661	CcSEcCtD
Epoprostenol—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000356	0.00066	CcSEcCtD
Epoprostenol—PTGIS—Disease—P4HB—osteoporosis	0.000355	0.00123	CbGpPWpGaD
Epoprostenol—Headache—Ethinyl Estradiol—osteoporosis	0.000354	0.000656	CcSEcCtD
Epoprostenol—Hypersensitivity—Zoledronate—osteoporosis	0.000353	0.000653	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—IL6—osteoporosis	0.000351	0.00121	CbGpPWpGaD
Epoprostenol—Vomiting—Risedronate—osteoporosis	0.00035	0.000649	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP27A1—osteoporosis	0.00035	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CNR2—osteoporosis	0.00035	0.00121	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—GAPDH—osteoporosis	0.000349	0.0012	CbGpPWpGaD
Epoprostenol—Rash—Risedronate—osteoporosis	0.000348	0.000644	CcSEcCtD
Epoprostenol—Dermatitis—Risedronate—osteoporosis	0.000347	0.000643	CcSEcCtD
Epoprostenol—Dizziness—Pamidronate—osteoporosis	0.000346	0.000642	CcSEcCtD
Epoprostenol—Headache—Risedronate—osteoporosis	0.000345	0.00064	CcSEcCtD
Epoprostenol—Asthenia—Zoledronate—osteoporosis	0.000343	0.000636	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ACP5—osteoporosis	0.000341	0.00117	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00034	0.000629	CcSEcCtD
Epoprostenol—Pruritus—Zoledronate—osteoporosis	0.000339	0.000627	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—PTH1R—osteoporosis	0.000337	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTH1R—osteoporosis	0.000337	0.00116	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CALCR—osteoporosis	0.000337	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CALCR—osteoporosis	0.000337	0.00116	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.000336	0.00116	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000336	0.000623	CcSEcCtD
Epoprostenol—Nausea—Ethinyl Estradiol—osteoporosis	0.000336	0.000622	CcSEcCtD
Epoprostenol—Insomnia—Estradiol—osteoporosis	0.000334	0.000618	CcSEcCtD
Epoprostenol—Vomiting—Pamidronate—osteoporosis	0.000333	0.000617	CcSEcCtD
Epoprostenol—PTGIS—Disease—NFATC1—osteoporosis	0.000331	0.00114	CbGpPWpGaD
Epoprostenol—Paraesthesia—Estradiol—osteoporosis	0.000331	0.000614	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000331	0.00114	CbGpPWpGaD
Epoprostenol—Asthenia—Conjugated Estrogens—osteoporosis	0.000331	0.000613	CcSEcCtD
Epoprostenol—Rash—Pamidronate—osteoporosis	0.00033	0.000612	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—PTH—osteoporosis	0.00033	0.00114	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PTH—osteoporosis	0.00033	0.00114	CbGpPWpGaD
Epoprostenol—Dermatitis—Pamidronate—osteoporosis	0.00033	0.000612	CcSEcCtD
Epoprostenol—PTGIS—Disease—DKK1—osteoporosis	0.000329	0.00113	CbGpPWpGaD
Epoprostenol—Dyspnoea—Estradiol—osteoporosis	0.000329	0.000609	CcSEcCtD
Epoprostenol—Headache—Pamidronate—osteoporosis	0.000328	0.000608	CcSEcCtD
Epoprostenol—Somnolence—Estradiol—osteoporosis	0.000328	0.000608	CcSEcCtD
Epoprostenol—Diarrhoea—Zoledronate—osteoporosis	0.000327	0.000607	CcSEcCtD
Epoprostenol—Nausea—Risedronate—osteoporosis	0.000327	0.000607	CcSEcCtD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000327	0.00113	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000326	0.00113	CbGpPWpGaD
Epoprostenol—Pruritus—Conjugated Estrogens—osteoporosis	0.000326	0.000604	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PTH—osteoporosis	0.000326	0.00112	CbGpPWpGaD
Epoprostenol—Dyspepsia—Estradiol—osteoporosis	0.000325	0.000602	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—CNR2—osteoporosis	0.000322	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CNR2—osteoporosis	0.000322	0.00111	CbGpPWpGaD
Epoprostenol—Decreased appetite—Estradiol—osteoporosis	0.000321	0.000594	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Estradiol—osteoporosis	0.000318	0.00059	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000318	0.0011	CbGpPWpGaD
Epoprostenol—Fatigue—Estradiol—osteoporosis	0.000318	0.000589	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CNR2—osteoporosis	0.000318	0.0011	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—WNT1—osteoporosis	0.000317	0.00109	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TPI1—osteoporosis	0.000317	0.00109	CbGpPWpGaD
Epoprostenol—Dizziness—Zoledronate—osteoporosis	0.000316	0.000586	CcSEcCtD
Epoprostenol—Constipation—Estradiol—osteoporosis	0.000315	0.000584	CcSEcCtD
Epoprostenol—Pain—Estradiol—osteoporosis	0.000315	0.000584	CcSEcCtD
Epoprostenol—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000315	0.000584	CcSEcCtD
Epoprostenol—Nausea—Pamidronate—osteoporosis	0.000311	0.000577	CcSEcCtD
Epoprostenol—PTGIS—Disease—FGA—osteoporosis	0.000308	0.00106	CbGpPWpGaD
Epoprostenol—Dizziness—Conjugated Estrogens—osteoporosis	0.000305	0.000565	CcSEcCtD
Epoprostenol—Vomiting—Zoledronate—osteoporosis	0.000304	0.000564	CcSEcCtD
Epoprostenol—Rash—Zoledronate—osteoporosis	0.000302	0.000559	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Estradiol—osteoporosis	0.000302	0.000559	CcSEcCtD
Epoprostenol—Dermatitis—Zoledronate—osteoporosis	0.000301	0.000559	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—PTH—osteoporosis	0.0003	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTH—osteoporosis	0.0003	0.00103	CbGpPWpGaD
Epoprostenol—Headache—Zoledronate—osteoporosis	0.0003	0.000556	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—WNT1—osteoporosis	0.000299	0.00103	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—P4HB—osteoporosis	0.000298	0.00103	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PTHLH—osteoporosis	0.000297	0.00103	CbGpPWpGaD
Epoprostenol—Vomiting—Conjugated Estrogens—osteoporosis	0.000293	0.000543	CcSEcCtD
Epoprostenol—Urticaria—Estradiol—osteoporosis	0.000293	0.000543	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000293	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000293	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CNR2—osteoporosis	0.000292	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CNR2—osteoporosis	0.000292	0.00101	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GAPDH—osteoporosis	0.000292	0.00101	CbGpPWpGaD
Epoprostenol—Abdominal pain—Estradiol—osteoporosis	0.000292	0.00054	CcSEcCtD
Epoprostenol—Body temperature increased—Estradiol—osteoporosis	0.000292	0.00054	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—MGLL—osteoporosis	0.000291	0.001	CbGpPWpGaD
Epoprostenol—Rash—Conjugated Estrogens—osteoporosis	0.000291	0.000538	CcSEcCtD
Epoprostenol—Dermatitis—Conjugated Estrogens—osteoporosis	0.00029	0.000538	CcSEcCtD
Epoprostenol—Headache—Conjugated Estrogens—osteoporosis	0.000289	0.000535	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—RAP1A—osteoporosis	0.000285	0.000982	CbGpPWpGaD
Epoprostenol—Nausea—Zoledronate—osteoporosis	0.000284	0.000527	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—LRP5—osteoporosis	0.000284	0.00098	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—WNT1—osteoporosis	0.000275	0.000948	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—WNT1—osteoporosis	0.000275	0.000948	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ENO1—osteoporosis	0.000275	0.000947	CbGpPWpGaD
Epoprostenol—Nausea—Conjugated Estrogens—osteoporosis	0.000274	0.000507	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—PTHLH—osteoporosis	0.000274	0.000944	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PTHLH—osteoporosis	0.000274	0.000944	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LRP6—osteoporosis	0.000272	0.000938	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Estradiol—osteoporosis	0.000272	0.000504	CcSEcCtD
Epoprostenol—PTGIS—Disease—PSMA2—osteoporosis	0.000271	0.000934	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PSMA5—osteoporosis	0.000271	0.000934	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PTHLH—osteoporosis	0.00027	0.000932	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MGLL—osteoporosis	0.000268	0.000924	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MGLL—osteoporosis	0.000268	0.000924	CbGpPWpGaD
Epoprostenol—Asthenia—Estradiol—osteoporosis	0.000265	0.00049	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CALCA—osteoporosis	0.000262	0.000903	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LRP5—osteoporosis	0.000262	0.000902	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LRP5—osteoporosis	0.000262	0.000902	CbGpPWpGaD
Epoprostenol—Pruritus—Estradiol—osteoporosis	0.000261	0.000484	CcSEcCtD
Epoprostenol—Diarrhoea—Estradiol—osteoporosis	0.000252	0.000468	CcSEcCtD
Epoprostenol—PTGIS—Disease—CALCA—osteoporosis	0.000252	0.00087	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LRP6—osteoporosis	0.00025	0.000863	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LRP6—osteoporosis	0.00025	0.000863	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTHLH—osteoporosis	0.000249	0.000857	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PTHLH—osteoporosis	0.000249	0.000857	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000248	0.000856	CbGpPWpGaD
Epoprostenol—Dizziness—Estradiol—osteoporosis	0.000244	0.000452	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000243	0.000837	CbGpPWpGaD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000242	0.000836	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—POMC—osteoporosis	0.000242	0.000836	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CALCA—osteoporosis	0.000241	0.000831	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CALCA—osteoporosis	0.000241	0.000831	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CALCA—osteoporosis	0.000238	0.00082	CbGpPWpGaD
Epoprostenol—Vomiting—Estradiol—osteoporosis	0.000235	0.000435	CcSEcCtD
Epoprostenol—Rash—Estradiol—osteoporosis	0.000233	0.000431	CcSEcCtD
Epoprostenol—Dermatitis—Estradiol—osteoporosis	0.000232	0.000431	CcSEcCtD
Epoprostenol—Headache—Estradiol—osteoporosis	0.000231	0.000428	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ENO1—osteoporosis	0.00023	0.000793	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TLN1—osteoporosis	0.00023	0.000792	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KL—osteoporosis	0.000229	0.00079	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PSMA2—osteoporosis	0.000227	0.000782	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PSMA5—osteoporosis	0.000227	0.000782	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—POMC—osteoporosis	0.000223	0.00077	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—POMC—osteoporosis	0.000223	0.00077	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000221	0.000763	CbGpPWpGaD
Epoprostenol—Nausea—Estradiol—osteoporosis	0.000219	0.000406	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CALCA—osteoporosis	0.000219	0.000755	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CALCA—osteoporosis	0.000219	0.000755	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TLN1—osteoporosis	0.000211	0.000729	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TLN1—osteoporosis	0.000211	0.000729	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.00021	0.000723	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IGF1—osteoporosis	0.000209	0.000719	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—P4HB—osteoporosis	0.000198	0.000683	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000197	0.000678	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTH—osteoporosis	0.000193	0.000664	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IGF1—osteoporosis	0.000192	0.000662	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAP1A—osteoporosis	0.000189	0.000653	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CNR2—osteoporosis	0.000188	0.000647	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—ADCY5—osteoporosis	0.000186	0.000643	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFATC1—osteoporosis	0.000185	0.000637	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP19A1—osteoporosis	0.000184	0.000634	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DKK1—osteoporosis	0.000183	0.000632	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—P4HB—osteoporosis	0.000182	0.000628	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—P4HB—osteoporosis	0.000182	0.000628	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ADCY5—osteoporosis	0.000179	0.000619	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTH—osteoporosis	0.000177	0.000611	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTH—osteoporosis	0.000177	0.000611	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—WNT1—osteoporosis	0.000176	0.000609	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAP1A—osteoporosis	0.000174	0.000601	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAP1A—osteoporosis	0.000174	0.000601	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	0.000174	0.000599	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CNR2—osteoporosis	0.000173	0.000596	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CNR2—osteoporosis	0.000173	0.000596	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000172	0.000593	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGA—osteoporosis	0.000172	0.000592	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—ADCY5—osteoporosis	0.000171	0.000591	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—ADCY5—osteoporosis	0.000171	0.000591	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	0.000171	0.000591	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFATC1—osteoporosis	0.00017	0.000586	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFATC1—osteoporosis	0.00017	0.000586	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ADCY5—osteoporosis	0.000169	0.000583	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DKK1—osteoporosis	0.000169	0.000581	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DKK1—osteoporosis	0.000169	0.000581	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTHFR—osteoporosis	0.000165	0.000569	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000163	0.000562	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—WNT1—osteoporosis	0.000162	0.00056	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—WNT1—osteoporosis	0.000162	0.00056	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTHLH—osteoporosis	0.00016	0.00055	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BMP2—osteoporosis	0.00016	0.00055	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000159	0.000548	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGA—osteoporosis	0.000158	0.000545	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGA—osteoporosis	0.000158	0.000545	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IRS2—osteoporosis	0.000157	0.000541	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGB—osteoporosis	0.000156	0.000539	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ADCY5—osteoporosis	0.000156	0.000537	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—ADCY5—osteoporosis	0.000156	0.000537	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PSMA5—osteoporosis	0.000151	0.00052	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PSMA2—osteoporosis	0.000151	0.00052	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ADCY5—osteoporosis	0.00015	0.000518	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GPX1—osteoporosis	0.00015	0.000517	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BMP2—osteoporosis	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTHLH—osteoporosis	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BMP2—osteoporosis	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTHLH—osteoporosis	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGB—osteoporosis	0.000144	0.000496	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGB—osteoporosis	0.000144	0.000496	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CALCA—osteoporosis	0.00014	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSMA2—osteoporosis	0.000139	0.000479	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSMA5—osteoporosis	0.000139	0.000479	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSMA2—osteoporosis	0.000139	0.000479	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSMA5—osteoporosis	0.000139	0.000479	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MTHFR—osteoporosis	0.000138	0.000477	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IRS1—osteoporosis	0.000137	0.000473	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—POMC—osteoporosis	0.000137	0.000473	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CALCA—osteoporosis	0.000129	0.000446	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CALCA—osteoporosis	0.000129	0.000446	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6R—osteoporosis	0.000129	0.000444	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KL—osteoporosis	0.000128	0.00044	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000127	0.000438	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—POMC—osteoporosis	0.000126	0.000435	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—POMC—osteoporosis	0.000126	0.000435	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—osteoporosis	0.000125	0.000431	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—POMC—osteoporosis	0.000124	0.000429	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6R—osteoporosis	0.000121	0.000419	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KL—osteoporosis	0.000117	0.000405	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KL—osteoporosis	0.000117	0.000405	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—osteoporosis	0.000115	0.000397	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—POMC—osteoporosis	0.000114	0.000395	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—POMC—osteoporosis	0.000114	0.000395	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6R—osteoporosis	0.000112	0.000385	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6R—osteoporosis	0.000112	0.000385	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—POMC—osteoporosis	0.000111	0.000381	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000108	0.000373	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—POMC—osteoporosis	0.000104	0.00036	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ADCY5—osteoporosis	9.99e-05	0.000345	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PKM—osteoporosis	9.85e-05	0.00034	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FDPS—osteoporosis	9.85e-05	0.00034	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SPP1—osteoporosis	9.67e-05	0.000333	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PGLS—osteoporosis	9.34e-05	0.000322	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPD2—osteoporosis	9.34e-05	0.000322	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ADCY5—osteoporosis	9.2e-05	0.000317	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ADCY5—osteoporosis	9.2e-05	0.000317	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SPP1—osteoporosis	8.9e-05	0.000307	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SPP1—osteoporosis	8.9e-05	0.000307	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IRS2—osteoporosis	8.74e-05	0.000302	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—osteoporosis	8.56e-05	0.000295	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PNP—osteoporosis	8.54e-05	0.000295	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ATIC—osteoporosis	8.54e-05	0.000295	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—osteoporosis	8.17e-05	0.000282	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IRS2—osteoporosis	8.05e-05	0.000278	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IRS2—osteoporosis	8.05e-05	0.000278	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—osteoporosis	7.87e-05	0.000272	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—osteoporosis	7.87e-05	0.000272	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IRS1—osteoporosis	7.63e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—osteoporosis	7.63e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—osteoporosis	7.61e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—osteoporosis	7.52e-05	0.000259	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—osteoporosis	7.52e-05	0.000259	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—POMC—osteoporosis	7.35e-05	0.000254	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA2—osteoporosis	7.26e-05	0.00025	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—OXCT1—osteoporosis	7.26e-05	0.00025	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6R—osteoporosis	7.17e-05	0.000247	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MGLL—osteoporosis	7.08e-05	0.000244	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—osteoporosis	7.07e-05	0.000244	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IRS1—osteoporosis	7.02e-05	0.000242	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IRS1—osteoporosis	7.02e-05	0.000242	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—POMC—osteoporosis	6.76e-05	0.000233	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—POMC—osteoporosis	6.76e-05	0.000233	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.67e-05	0.00023	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6R—osteoporosis	6.6e-05	0.000228	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6R—osteoporosis	6.6e-05	0.000228	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—osteoporosis	6.51e-05	0.000224	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—osteoporosis	6.51e-05	0.000224	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—IDH2—osteoporosis	6.02e-05	0.000208	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—osteoporosis	5.73e-05	0.000198	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP27A1—osteoporosis	5.66e-05	0.000195	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACP5—osteoporosis	5.5e-05	0.00019	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.43e-05	0.000187	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—osteoporosis	5.41e-05	0.000186	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TPI1—osteoporosis	5.12e-05	0.000176	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—osteoporosis	4.98e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—osteoporosis	4.98e-05	0.000172	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—P4HB—osteoporosis	4.81e-05	0.000166	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GAPDH—osteoporosis	4.72e-05	0.000163	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RAP1A—osteoporosis	4.6e-05	0.000159	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—osteoporosis	4.25e-05	0.000147	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—osteoporosis	4.24e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.01e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—osteoporosis	3.91e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—osteoporosis	3.91e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—osteoporosis	3.9e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—osteoporosis	3.9e-05	0.000135	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO1—osteoporosis	3.72e-05	0.000128	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMA5—osteoporosis	3.66e-05	0.000126	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMA2—osteoporosis	3.66e-05	0.000126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—osteoporosis	3.19e-05	0.00011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP19A1—osteoporosis	2.97e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—osteoporosis	2.94e-05	0.000101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—osteoporosis	2.94e-05	0.000101	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADCY5—osteoporosis	2.43e-05	8.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—osteoporosis	2.42e-05	8.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—osteoporosis	2.23e-05	7.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POMC—osteoporosis	1.79e-05	6.16e-05	CbGpPWpGaD
